DE69800906D1 - Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie - Google Patents

Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie

Info

Publication number
DE69800906D1
DE69800906D1 DE69800906T DE69800906T DE69800906D1 DE 69800906 D1 DE69800906 D1 DE 69800906D1 DE 69800906 T DE69800906 T DE 69800906T DE 69800906 T DE69800906 T DE 69800906T DE 69800906 D1 DE69800906 D1 DE 69800906D1
Authority
DE
Germany
Prior art keywords
olanzapine
medicament
manufacture
treatment
focal ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69800906T
Other languages
English (en)
Other versions
DE69800906T2 (de
Inventor
Franklin Porter Bymaster
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69800906D1 publication Critical patent/DE69800906D1/de
Publication of DE69800906T2 publication Critical patent/DE69800906T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • External Artificial Organs (AREA)
  • Eye Examination Apparatus (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE69800906T 1997-04-15 1998-04-09 Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie Expired - Fee Related DE69800906T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4309597P 1997-04-15 1997-04-15

Publications (2)

Publication Number Publication Date
DE69800906D1 true DE69800906D1 (de) 2001-07-19
DE69800906T2 DE69800906T2 (de) 2001-11-15

Family

ID=21925477

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69800906T Expired - Fee Related DE69800906T2 (de) 1997-04-15 1998-04-09 Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie

Country Status (11)

Country Link
EP (1) EP0872239B1 (de)
AT (1) ATE201993T1 (de)
AU (1) AU6896198A (de)
DE (1) DE69800906T2 (de)
DK (1) DK0872239T3 (de)
ES (1) ES2158647T3 (de)
GR (1) GR3036260T3 (de)
PT (1) PT872239E (de)
SI (1) SI0872239T1 (de)
WO (1) WO1998046230A1 (de)
ZA (1) ZA982917B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155696B1 (de) * 1997-04-15 2004-03-03 Eli Lilly And Company Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
WO2002013870A2 (en) * 2000-08-17 2002-02-21 Mitokor, Inc. Formulation for administering therapeutic lipophilic molecules
DE112005000641T5 (de) * 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5744470A (en) * 1996-03-11 1998-04-28 Eli Lilly And Company Method for treating insomnia

Also Published As

Publication number Publication date
AU6896198A (en) 1998-11-11
EP0872239A2 (de) 1998-10-21
EP0872239B1 (de) 2001-06-13
PT872239E (pt) 2001-09-28
ATE201993T1 (de) 2001-06-15
SI0872239T1 (en) 2001-10-31
ZA982917B (en) 1999-10-06
DK0872239T3 (da) 2001-09-03
ES2158647T3 (es) 2001-09-01
GR3036260T3 (en) 2001-10-31
EP0872239A3 (de) 1998-10-28
DE69800906T2 (de) 2001-11-15
WO1998046230A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
BR9708037A (pt) Método para o tratamento de abuso de substância
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
DE69822234D1 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee